Krsnaa Diagnostics: Navigating Growth and Strategic Expansion in Q3 & 9M FY26

Krsnaa Diagnostics Limited, a leading integrated diagnostic service provider in India, has reported its financial performance for the third quarter and nine months ended December 31, 2025 (FY26). The company demonstrated resilience amidst seasonal challenges and strategic expansion initiatives, showcasing a robust underlying business model focused on long-term value creation. For Q3 FY26, Krsnaa Diagnostics recorded a consolidated revenue from operations of INR 181.2 crore, marking a 4% year-on-year growth. The nine-month period saw a revenue of INR 580.2 crore, reflecting a healthy 9% increase compared to the previous year. Despite initial cost absorption from new projects, the company maintained an EBITDA of INR 46.4 crore for Q3 FY26, with a PAT of INR 15.2 crore.

The quarter's performance was influenced by typical seasonal softness and festive periods, which led to lower volumes. Additionally, the company made conscious decisions to temporarily pause operations in certain projects to accelerate the recovery of long-pending government receivables. This strategic move proved beneficial, as Krsnaa Diagnostics successfully recovered over INR 130 crore in Q3 FY26, an impressive INR 100 crore more than the same quarter last year. This significantly bolstered the company's cash position and underscored its disciplined approach to working capital management. The management emphasized that while such decisions might impact near-term optics, they are crucial for building a sustainable and impactful healthcare institution over decades.

Strategic Initiatives Driving Future Growth

Krsnaa Diagnostics is actively pursuing several key strategic initiatives designed to expand its footprint and diversify its service offerings. A significant milestone is the launch of the first Apulki Healthcare Hospital in Pune. This 150-bedded facility, established in association with the Pune Municipal Corporation, is India's first PPP-based cancer and cardiac care hospital. It offers comprehensive cancer treatment at CGHS rates, operating on a cash and carry model. This venture represents a calibrated extension of Krsnaa's capabilities into integrated tertiary care, built on the same successful PPP principles. The company anticipates this hospital will achieve mature annual revenues of approximately INR 20 crore within 2 to 3 years, with plans to operationalize four more hospitals, adding a total capacity of 600 beds.

Another major undertaking is the Rajasthan pathology project rollout, which involves establishing around 20 pathology labs and approximately 300 collection centers. This project is expected to be largely operational by Q4 FY26, with some spillover into Q1 FY27. Management projects an annualized revenue contribution of INR 200 crore from Rajasthan by the end of FY27, which is expected to significantly increase pathology's share in the company's overall revenue to 65-70%. While this project entails initial cost absorption for infrastructure and personnel, the company is focused on minimizing its impact on overall margins.

Expanding Reach and Operational Excellence

Krsnaa Diagnostics continues to strengthen its core diagnostic network. The Maharashtra radiology project is underway, with plans to add 10 new MRI centers. Despite some delays in site clearances and inaugurations, the company expects to implement some of these sites in Q4 FY26, with revenue contributions anticipated in subsequent quarters. This expansion will further solidify Krsnaa's position as one of Asia's largest radiology players, with over 200 CT/MRI centers upon completion of its existing order book.

The retail diagnostic segment is emerging as a powerful growth engine. In Q3 FY26, retail revenue grew by an impressive 8x year-on-year, contributing approximately 8% to the group's revenue in 9M FY26. The company has expanded its retail network to over 3,000 touch points across Maharashtra, Punjab, Assam, and Odisha, focusing on B2C engagement, home collection services, and preventive healthcare offerings. This segment is seen as a crucial second engine of growth alongside the PPP model.

Krsnaa Diagnostics also maintains a sharp focus on operational efficiencies and technology-led automation. Efforts in manpower deployment, asset utilization, and procurement have improved asset productivity and reduced equipment downtime. Investments in centralized monitoring, automated reporting, and billing systems are enhancing operating efficiency, cash conversion cycles, and patient experience. The company's commitment to quality is evident through its extensive accreditations, including 49 NABH accredited radiology centers, 57 NABL accredited laboratories, India's first CAP accredited pathology lab, and the country's first ACR recognized tele-radiology hub.

Financial Summary Table

Outlook and Investor Confidence

Krsnaa Diagnostics' strategy is rooted in building a resilient healthcare infrastructure platform supported by long-term PPP contracts, wide geographic reach, predictable revenue visibility, and structurally lower customer acquisition costs. The company's ability to operate profitably while offering services at 50-70% below market rates highlights its efficiency and impact. The Union Budget's increased allocation for healthcare infrastructure further reinforces the favorable environment for Krsnaa's PPP model. While the company acknowledges temporary impacts from expansion costs and project delays, it remains confident in its strategy, disciplined capital allocation, and commitment to delivering superior quality diagnostics at scale. The management's focus on strengthening cash flows and achieving full annualized revenues from new projects by FY27 signals a clear path towards sustained growth and enhanced shareholder value.

Krsnaa Diagnostics is not merely a short-cycle business; it is a long-term healthcare institution designed to compound value over decades. The company's disciplined execution and strategic expansions position it well to capitalize on India's growing demand for accessible and affordable diagnostic services, reinforcing investor trust in its foundational role in the country's healthcare landscape.